Sign In
Buy BDSX
$19.16
+1.81 (+10.43%)
At Close: Jun 23, 2026
Biodesix (BDSX) Surges 10.5%: Is This an Indication of Further Gains?
05:31am, Friday, 19'th Jun 2026
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Are Medical Stocks Lagging Biodesix (BDSX) This Year?
10:41am, Monday, 15'th Jun 2026
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.
3 Medical Service Industry Stocks Thriving Amid Workforce Challenges
09:26am, Monday, 08'th Jun 2026
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade
10:56am, Monday, 25'th May 2026
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Biodesix to Participate in Upcoming Investor Conferences
06:00am, Thursday, 21'st May 2026
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participat
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professional
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect?
10:55am, Thursday, 07'th May 2026
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
07:53pm, Monday, 04'th May 2026
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates
06:10pm, Monday, 04'th May 2026
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.
Biodesix Announces First Quarter 2026 Results and Highlights
04:01pm, Monday, 04'th May 2026
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conf
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
06:00am, Monday, 20'th Apr 2026
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarte
Comparing Biodesix (NASDAQ:BDSX) & Bausch + Lomb (NYSE:BLCO)
04:32am, Friday, 10'th Apr 2026
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on
Biodesix Recognized as a Top Workplace for Third Consecutive Year
01:19pm, Thursday, 09'th Apr 2026
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Culture Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix
Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development
11:43am, Monday, 06'th Apr 2026
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing Includes novel proteomic and genomic approaches to
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent clinical performance across nodule sizes and patient populations A retrospective pooled analysis of 1,
